Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

Differential deficits in pattern- versus flash-visual evoked potentials in schizophrenia: relationship to subcortical visual systems, pulvinar nucleus and cognition.

Frontiers in neuroimaging·2026
Same author

Correction: Ten years of the European association of endoscopic surgery (EAES) fellowship programme: outcomes and future perspective.

Surgical endoscopy·2026
Same author

Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.

bioRxiv : the preprint server for biology·2026
Same author

Serotonin type 3 receptor (5-HT<sub>3</sub>R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Correction: Manifesto of the collaborative alliance for research and educationin surgery: the CARES network. "Surgical research must become amilestone of progress in patient care in Italy".

Updates in surgery·2026

Related Experiment Video

Updated: Jul 25, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.

Andrea Balla1, Henry Sershen, Michael Serra

  • 1Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, NY 10962, USA.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|December 24, 2002
PubMed
Summary

Phencyclidine (PCP) treatment in rats enhances amphetamine-induced dopamine release in the prefrontal cortex, mimicking schizophrenia's dopaminergic hyperactivity. This effect, linked to NMDA receptor dysfunction, highlights risks of PCP-like substance abuse.

More Related Videos

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

Related Experiment Videos

Last Updated: Jul 25, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Functional dopaminergic hyperactivity is a hallmark of schizophrenia, but its origins remain unclear.
  • Subchronic phencyclidine (PCP) administration in rodents models this striatal dopaminergic hyperactivity.
  • PCP's effects on dopamine release in the prefrontal cortex (PFC) and nucleus accumbens (NAc) are key to understanding schizophrenia's cognitive deficits.

Purpose of the Study:

  • To investigate PCP's potentiation of amphetamine-induced dopamine release in the rat PFC and NAc shell.
  • To explore the correlation between PCP-induced hyperactivity and dopamine levels in the PFC versus NAc.
  • To establish a rodent model for evaluating potential psychotherapeutic agents for schizophrenia.

Main Methods:

  • Rats received daily PCP doses (5-20 mg/kg) via osmotic minipump for 3-14 days.
  • In vivo microdialysis and HPLC-EC were used to monitor dopamine release in the PFC and NAc following amphetamine challenge (1 mg/kg).
  • Serum PCP concentrations were measured to correlate with human PCP psychosis levels.

Main Results:

  • PCP treatment (10 mg/kg/day and above) significantly enhanced amphetamine-induced dopamine release in the PFC, but not the NAc, in a dose-dependent manner.
  • Locomotor activity was also significantly increased in PCP-treated rats.
  • These effects were observed after both 3-day and 14-day PCP treatments and resolved within 4 days of withdrawal.

Conclusions:

  • Endogenous NMDA receptor dysfunction may underlie the dopaminergic dysfunction seen in schizophrenia.
  • Short-term abuse of PCP-like substances can significantly potentiate psychostimulant effects, relevant to drug abuse scenarios.
  • The study provides a valuable model for testing novel psychotherapeutic interventions for schizophrenia.